Cancer Genetics Incorporated (NASDAQ:CGIX) had an increase of 2.95% in short interest. CGIX’s SI was 1.27 million shares in December as released by FINRA. Its up 2.95% from 1.23 million shares previously. With 116,700 avg volume, 11 days are for Cancer Genetics Incorporated (NASDAQ:CGIX)’s short sellers to cover CGIX’s short positions. The SI to Cancer Genetics Incorporated’s float is 9.45%. The stock decreased 1.05% or $0.03 during the last trading session, reaching $2.35. About 40,268 shares traded. Cancer Genetics, Inc. (NASDAQ:CGIX) has risen 81.82% since December 1, 2016 and is uptrending. It has outperformed by 65.12% the S&P500.
The stock of Cross Country Healthcare, Inc. (NASDAQ:CCRN) is a huge mover today! The stock decreased 3.29% or $0.45 during the last trading session, reaching $13.22. About 127,824 shares traded. Cross Country Healthcare, Inc. (NASDAQ:CCRN) has declined 8.78% since December 1, 2016 and is downtrending. It has underperformed by 25.48% the S&P500.The move comes after 8 months negative chart setup for the $482.28M company. It was reported on Dec, 1 by Barchart.com. We have $12.29 PT which if reached, will make NASDAQ:CCRN worth $33.76M less.
Among 9 analysts covering Cross Country Healthcare (NASDAQ:CCRN), 6 have Buy rating, 0 Sell and 3 Hold. Therefore 67% are positive. Cross Country Healthcare had 15 analyst reports since August 9, 2015 according to SRatingsIntel. The firm earned “Mkt Perform” rating on Tuesday, January 24 by Avondale. As per Wednesday, August 2, the company rating was maintained by Oppenheimer. The stock of Cross Country Healthcare, Inc. (NASDAQ:CCRN) earned “Buy” rating by Benchmark on Friday, January 20. Cantor Fitzgerald maintained Cross Country Healthcare, Inc. (NASDAQ:CCRN) on Thursday, July 6 with “Buy” rating. UBS maintained Cross Country Healthcare, Inc. (NASDAQ:CCRN) on Friday, March 11 with “Buy” rating. The firm has “Buy” rating by BMO Capital Markets given on Sunday, October 8. The company was maintained on Tuesday, July 11 by BMO Capital Markets. The rating was maintained by Cantor Fitzgerald with “Buy” on Friday, November 6. The stock of Cross Country Healthcare, Inc. (NASDAQ:CCRN) has “Buy” rating given on Wednesday, June 14 by Cantor Fitzgerald. The stock of Cross Country Healthcare, Inc. (NASDAQ:CCRN) has “Buy” rating given on Wednesday, October 18 by SunTrust.
Cross Country Healthcare, Inc. provides healthcare staffing, recruiting, and workforce solutions in the United States. The company has market cap of $482.28 million. The firm operates through three divisions: Nurse and Allied Staffing, Physician Staffing, and Other Human Capital Management Services. It has a 48.78 P/E ratio. The Nurse and Allied Staffing segment offers traditional staffing, including temporary and permanent placement of travel nurses and allied professionals, and branch local nurses and allied staffing; and short-term staffing of registered nurses, licensed practical nurses, certified nurse assistants, practitioners, pharmacists, and other allied professionals on per diem and short-term assignments.
Investors sentiment decreased to 0.94 in 2017 Q2. Its down 0.53, from 1.47 in 2017Q1. It worsened, as 15 investors sold Cross Country Healthcare, Inc. shares while 48 reduced holdings. 14 funds opened positions while 45 raised stakes. 32.92 million shares or 1.26% more from 32.51 million shares in 2017Q1 were reported. Morgan Stanley reported 97,562 shares. Skyline Asset Mgmt L P holds 1.46M shares or 1.59% of its portfolio. Sector Pension Inv Board holds 0% or 16,973 shares. Eagle Boston Mgmt holds 636,420 shares. The Texas-based Ranger Investment Mgmt L P has invested 0.09% in Cross Country Healthcare, Inc. (NASDAQ:CCRN). Simcoe Cap Mgmt Ltd Liability reported 1.23M shares. Barclays Public Limited Company holds 0% or 3,883 shares in its portfolio. Citigroup Incorporated reported 0% stake. Jpmorgan Chase And holds 1.87M shares or 0.01% of its portfolio. State Of Alaska Department Of Revenue holds 6,315 shares. Ny State Teachers Retirement holds 0% or 68,856 shares in its portfolio. Guggenheim Llc accumulated 111,930 shares. Comml Bank Of America De, North Carolina-based fund reported 66,685 shares. Credit Suisse Ag holds 26,391 shares. Prudential Financial Inc holds 52,508 shares.
Analysts await Cross Country Healthcare, Inc. (NASDAQ:CCRN) to report earnings on March, 7. They expect $0.19 EPS, down 5.00% or $0.01 from last year’s $0.2 per share. CCRN’s profit will be $6.93 million for 17.39 P/E if the $0.19 EPS becomes a reality. After $0.23 actual EPS reported by Cross Country Healthcare, Inc. for the previous quarter, Wall Street now forecasts -17.39% negative EPS growth.
Since June 12, 2017, it had 1 insider purchase, and 0 sales for $374,870 activity. PAPPAJOHN JOHN had bought 100,000 shares worth $374,870.
Investors sentiment decreased to 1.17 in Q2 2017. Its down 1.54, from 2.71 in 2017Q1. It dropped, as 6 investors sold Cancer Genetics, Inc. shares while 6 reduced holdings. 5 funds opened positions while 9 raised stakes. 2.76 million shares or 20.57% more from 2.29 million shares in 2017Q1 were reported. The Minnesota-based Perkins Cap Incorporated has invested 3.63% in Cancer Genetics, Inc. (NASDAQ:CGIX). Deutsche National Bank & Trust Ag holds 300 shares. Diker Mngmt Limited Co has invested 0.11% of its portfolio in Cancer Genetics, Inc. (NASDAQ:CGIX). Granahan Inv Ma reported 188,060 shares. Geode Limited Liability Corp invested in 87,279 shares or 0% of the stock. Blackrock has invested 0% in Cancer Genetics, Inc. (NASDAQ:CGIX). Royal Fincl Bank Of Canada invested in 0% or 5,276 shares. 454 were reported by Barclays Public Ltd Liability Company. Moreover, Next Financial Gp has 0% invested in Cancer Genetics, Inc. (NASDAQ:CGIX) for 2,500 shares. Panagora Asset Management Incorporated holds 0% or 6,449 shares in its portfolio. Vanguard Group has 0% invested in Cancer Genetics, Inc. (NASDAQ:CGIX). The New Jersey-based Jacobs Levy Equity Mgmt Inc has invested 0% in Cancer Genetics, Inc. (NASDAQ:CGIX). Renaissance Tech Limited Com owns 569,700 shares for 0% of their portfolio. Eagle Global Ltd holds 22,170 shares. Bank Of America Corp De reported 625 shares.
Cancer Genetics, Inc. develops, commercializes, and provides molecular and biomarker tests and services in the United States, India, and China. The company has market cap of $57.00 million. The Company’s tests enable physicians to personalize the clinical management of each individual patient by providing genomic information to diagnose, monitor, and inform cancer treatment; and enable biotech and pharmaceutical companies involved in oncology trials to select candidate populations and reduce adverse drug reactions by providing information regarding genomic factors influencing subject responses to therapeutics. It currently has negative earnings. The companyÂ’s clinical services provide information on diagnosis, prognosis, and predicting treatment outcomes of cancers to guide patient management.
Among 6 analysts covering Cancer Genetics (NASDAQ:CGIX), 5 have Buy rating, 0 Sell and 1 Hold. Therefore 83% are positive. Cancer Genetics had 8 analyst reports since March 11, 2016 according to SRatingsIntel. H.C. Wainwright maintained the shares of CGIX in report on Thursday, September 21 with “Buy” rating. The firm earned “Neutral” rating on Friday, March 11 by Janney Capital. H.C. Wainwright maintained Cancer Genetics, Inc. (NASDAQ:CGIX) rating on Tuesday, August 15. H.C. Wainwright has “Buy” rating and $600 target. Rodman & Renshaw initiated the shares of CGIX in report on Monday, September 26 with “Buy” rating. Aegis Capital maintained it with “Buy” rating and $8 target in Tuesday, March 15 report. H.C. Wainwright maintained it with “Buy” rating and $6.0 target in Wednesday, November 29 report.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.